We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+11.35%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$81.6B
AUM Growth
+$7.7B
(+10%)
Cap. Flow
+$798M
Cap. Flow
% of AUM
0.98%
Top 10 Holdings %
Top 10 Hldgs %
23.85%
Holding
3,095
New
53
Increased
1,513
Reduced
1,408
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$65.3M |
| 2 |
Amazon
AMZN
|
+$50M |
| 3 |
Tesla
TSLA
|
+$30.5M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$26.6M |
| 5 |
EPAM Systems
EPAM
|
+$26.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KSU
Kansas City Southern
KSU
|
+$39.1M |
| 2 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
+$31.2M |
| 3 |
XEC
CIMAREX ENERGY CO
XEC
|
+$23.4M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$21.9M |
| 5 |
SBNY
Signature Bank
SBNY
|
+$17.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.54% |
| 2 | Financials | 13.15% |
| 3 | Healthcare | 12.95% |
| 4 | Consumer Discretionary | 12.27% |
| 5 | Industrials | 8.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2776
Quince Therapeutics
QNCX
$29.5M
| $242K | ﹤0.01% |
96
-3
| -3% | -$18.3K |
|
2777
Stereotaxis
STXS
$141M
| $242K | ﹤0.01% |
39,011
-895
| -2% | -$5.35K |
|
2778
Viemed Healthcare
VMD
$371M
| $242K | ﹤0.01% |
46,265
-223
| -0.5% | -$1.24K |
|
|
INST
2779
DELISTED
Instructure Holdings, Inc.
INST
| $242K | ﹤0.01% |
10,073
-28
| -0.3% | -$678 |
|
2780
Atlanticus Holdings
ATLC
$1.52B
| $241K | ﹤0.01% |
+3,380
| New | +$226K |
|
2781
VirnetX Holding Corp
VHC
$63.1M
| $241K | ﹤0.01% |
4,643
-22
| -0.5% | -$1.53K |
|
2782
BioAtla
BCAB
$5.74M
| $240K | ﹤0.01% |
244
+17
| +7% | +$21.7K |
|
2783
Alaunos Therapeutics
TCRT
$4.86M
| $240K | ﹤0.01% |
1,470
-29
| -2% | -$6.37K |
|
2784
iRadimed
IRMD
$1.18B
| $239K | ﹤0.01% |
+5,178
| New | +$209K |
|
|
GTYH
2785
DELISTED
GTY Technology Holdings, Inc. Common Stock
GTYH
| $239K | ﹤0.01% |
35,600
-747
| -2% | -$5.3K |
|
2786
NI Holdings
NODK
$320M
| $237K | ﹤0.01% |
12,512
-466
| -4% | -$8.99K |
|
|
SQZ
2787
DELISTED
SQZ Biotechnologies Company
SQZ
| $236K | ﹤0.01% |
26,483
-403
| -1% | -$4.94K |
|
|
BFX
2788
DELISTED
BowFlex Inc.
BFX
| $234K | ﹤0.01% |
38,096
-923
| -2% | -$7.65K |
|
|
PRTK
2789
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $234K | ﹤0.01% |
52,155
-731
| -1% | -$3.47K |
|
|
AKUS
2790
DELISTED
Akouos Inc
AKUS
| $234K | ﹤0.01% |
27,471
-326
| -1% | -$2.92K |
|
|
IGMS
2791
DELISTED
IGM Biosciences
IGMS
| $232K | ﹤0.01% |
7,914
-142
| -2% | -$7.06K |
|
|
FTSI
2792
DELISTED
FTS International, Inc. Common Stock
FTSI
| $232K | ﹤0.01% |
8,841
+238
| +3% | +$6.27K |
|
2793
Escalade
ESCA
$311M
| $231K | ﹤0.01% |
14,660
-563
| -4% | -$10.2K |
|
2794
XBiotech
XBIT
$69.2M
| $231K | ﹤0.01% |
20,710
-535
| -3% | -$6.96K |
|
2795
Werewolf Therapeutics
HOWL
$19.3M
| $230K | ﹤0.01% |
+19,305
| New | +$291K |
|
2796
Taysha Gene Therapies
TSHA
$1.89B
| $230K | ﹤0.01% |
19,770
-361
| -2% | -$5.45K |
|
2797
UroGen Pharma
URGN
$2.29B
| $229K | ﹤0.01% |
24,064
-344
| -1% | -$4.85K |
|
|
SFT
2798
DELISTED
Shift Technologies, Inc. Class A Common Stock
SFT
| $228K | ﹤0.01% |
6,687
-352
| -5% | -$19.3K |
|
|
ADVM
2799
DELISTED
Adverum Biotechnologies
ADVM
| $227K | ﹤0.01% |
12,888
-28
| -0.2% | -$561 |
|
|
UDMY
2800
DELISTED
Udemy
UDMY
| $227K | ﹤0.01% |
+11,594
| New | +$278K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2021 Portfolio in Review
As of Q4 2021, RhumbLine Advisers held 3,095 positions worth $81.6B, up 10% from $73.9B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Trading was light in Q4 2021: portfolio turnover was 4.4%. RhumbLine Advisers opened 53 new positions and exited 84, leaving the 3,095-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2021 buy was Rivian: 125,331 shares worth $13M.
- RhumbLine Advisers added most to Microsoft in Q4 2021, an estimated $65.3M increase.
- RhumbLine Advisers's biggest Q4 2021 reduction was Berkshire Hathaway Class B, cutting an estimated $21.9M.
- RhumbLine Advisers fully exited Kansas City Southern in Q4 2021, selling an estimated $39.1M.
- RhumbLine Advisers's ten largest holdings make up 24% of its $81.6B portfolio in Q4 2021.
- RhumbLine Advisers opened 53 new positions and closed 84 in Q4 2021.
- RhumbLine Advisers's portfolio value rose 10% quarter-over-quarter to $81.6B.
Based on RhumbLine Advisers's 13F filing for Q4 2021, filed 10 Feb 2022.